Project Grant R01CA303538
Award Date 9/24/25
Completion Date 8/31/29
Dollars Obligated $3.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
- This federal Project Grant award of $663,340 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to elucidate the mechanisms by which the ablation of intratumoral regulatory T cells can mobilize NK cells and CD4 T cells to control MHC I-deficient tumors. The research aims to determine how CD4 T cell help enhances the antitumor function of NK cells, including the role of cytokines like IL-2 and IL-15, as well as test whether intratumoral Treg depletion...
- This federal Project Grant award of $312,892 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The grant supports research at Duke University to study the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The goal is to understand how ILC3s impact the effectiveness of immune checkpoint inhibitor (ICI) therapy for advanced melanoma patients, as the majority do not respond to ICI treatment....
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to Georgetown University for $109,386 provides funding to investigate strategies to increase the co-localization of activated natural killer (NK) cells with tumor cells in pancreatic ductal adenocarcinoma (PDAC). The research aims to explore how inhibiting dipeptidyl peptidases (DPPs) can enhance the efficacy of anti-PD1 immunotherapy by increasing NK cell infiltration and reducing fibrosis in...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $150,878 to the Regents of the University of Minnesota (doing business as the Office of Sponsored Projects Administration) to support research on tissue-resident adaptive CD56bright natural killer (NK) cell responses in cancer. The key objectives are to advance the understanding of the functions of CD56bright "bright-tank" NK cell populations in tumors and identify mechanisms...
- This Project Grant award of $124,134 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms of pathogenesis and treatment response in immune checkpoint inhibitor-induced colitis. The research aims to define the role of specific T cell subsets recruited from circulation in promoting inflammation and mediating therapeutic response in this condition, which can occur in up to 40% of cancer patients receiving immune checkpoint...
- The National Cancer Institute (NCI) awarded a $547,945 Project Grant under CFDA 93.396 (Cancer Biology Research) to The Johns Hopkins University to conduct research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The project aims to investigate how biological factors such as prior cardiac injury, age, and sex modulate the risk of this adverse event, which occurs in 1-2% of cancer patients receiving immune checkpoint inhibitor therapy but can be fatal in up to 50% of...
- This federal Project Grant award of $846,982 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports a research project titled "Navigating Pathways of Innate Immunity and Epigenetic Memory in Checkpoint Immunotherapy" at Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The research aims to advance the understanding of how the PD-1:SHP-2 axis in hematopoietic stem and progenitor cells impacts the differentiation and function of...
- This federal Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) provides $153,348 to The Trustees of Columbia University in the City of New York to conduct in-depth mechanistic and in vivo functional studies of single-nucleotide variants (SNVs) that modulate T cell activity for cancer immunotherapies. The research aims to define the mechanisms by which certain PIK3CD SNVs enhance T cell activity and evaluate their impact in murine...
- This Project Grant award of $754,511 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the Jackson Laboratory to discover host genetic factors that influence response to immune checkpoint inhibitor (ICI) cancer treatments. The project aims to: Expand and refine a mouse experimental platform to map quantitative trait loci (QTLs) associated with ICI response, focusing on defining the genetic mechanisms behind epistatic interactions. Challenge top...
- This Project Grant award, funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower), aims to investigate the potential of a de novo dietary compound called Sumiki's Acid (SKA) as an immunomodulator for cancer immunoprevention. The $113,203 award, granted on August 1, 2025, will support research to determine SKA's ability to enhance natural killer (NK) cell activation and cytotoxicity against cancer cells, as well as evaluate its cancer-preventive effects in mouse models. The...